David Rizzieri, MD

Quick facts

Phase 2 pipeline

• Campath Purged Non-myeloablative ASCT · Oncology
  Campath (Alemtuzumab) is a monoclonal antibody that targets CD52, a protein found on the surface of mature lymphocytes.
• Non-myeloablative Stem Cell Transplantation

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• David Rizzieri, MD portfolio CI brief
• David Rizzieri, MD pipeline updates RSS

Related

• Sector hub: All tracked pharma companies